Three and a Half Years of Multi-Allergen Subcutaneous Immunotherapy Is Associated with a 50% Reduction in Asthma Symptom Scores
Monday, March 7, 2016
South Exhibit Hall H (Convention Center)
Efren L. Rael, MD FAAAAI, Faoud T. Ishmael, MD PhD FAAAAI

Allergen immunotherapy is effective in improving allergic asthma1. Few studies assess efficacy of multi-allergen subcutaneous immunotherapy (SCIT) in relation to asthma.  


After institutional review board approval and informed consent, a real world, single center observational study from an academic center in Pennsylvania was conducted.  Sixty-three subjects with asthma and allergic rhinitis diagnosed by skin prick puncture, plus or minus intradermal testing or by immunocap testing were followed for up to 5 years.   Average subject age was 33.5 years with 67% female.  Immunotherapy treatments were conducted per immunotherapy practice parameters as published in the Journal of Allergy and Clinical Immunology2.   Subjects on average were treated with a combination of 15 allergens. 


The average ACQ score for the group at initiation of immunotherapy was 1.02.  A 50 percent average reduction in ACQ scores was achieved by year 3.5.  


Multi-allergen SCIT is effective in improving asthma symptoms.  A subset of subjects were non-responsive to therapy.  Further work is necessary to address non-responsiveness to allergen immunotherapy.